OncLive TV

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), a 2017 Giant of Cancer Care® in Lung Cancer, discusses the idea for an online treatment decision tool for lung cancer.

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses unmet needs in the treatment of patients with neuroendocrine tumors.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses recent advances in the treatment of patients with hormone receptor-positive breast cancer.

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events related to BTK inhibitors in the treatment of mantle cell lymphoma.

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.

Laurence J. Heifetz, MD, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses rural oncology care.

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential of combination therapy in hepatocellular carcinoma.

Jay Yang, MD, oncologist, Barbara Ann Karmanos Cancer Institute, discusses the future of acute myeloid leukemia (AML).

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses the future of venetoclax (Venclexta) in the treatment of chronic lymphocytic leukemia (CLL).

Jorge E. Cortes, MD, professor and deputy chair, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses quizartinib for the treatment of patients with acute myeloid leukemia.

Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses implementing geriatric assessments into cancer care.

Nathan A. Pennell, MD, PhD, director, Lung Cancer Medical Oncology Program, Cleveland Clinic Taussig Cancer Institute, discusses the cost-effectiveness of next-generation sequencing for patients with metastatic non–small cell lung cancer.

Jeffrey Zonder, MD, associate professor of oncology and medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses induction therapy in the treatment of patients with newly diagnosed multiple myeloma.

Joshua Meeks, MD, PhD, assistant professor of urology, biochemistry, and molecular genetics, Northwestern University Feinberg School of Medicine, section chief of robotic surgery, Jesse Brown VA Medical Center, discusses the genomics of bladder cancer.

Joseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the use of transplant in myelodysplastic syndrome (MDS).

Augusto Villanueva, MD, PhD, assistant professor, Icahn School of Medicine, discusses remaining challenges with liquid biopsies in hepatocellular carcinoma.

Brian T. Burgess, DO, first-year fellow, University of Kentucky Markey Cancer Center, discusses resistance to PARP inhibitors in patients with ovarian cancer.

Geoffrey R. Oxnard, MD, associate professor of medicine, Harvard Medical School, thoracic oncologist, medical oncology, Dana-Farber Cancer Institute, discusses the potential impact of implementing cell-free DNA tests as a method to detect signs of early stage cancer.

Robert J. Kreitman, MD, chief, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, discusses the prognosis for patients diagnosed with hairy cell leukemia.

Erlene Seymour, MD, an oncologist at Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses shifting standards of care in chronic lymphocytic leukemia (CLL).

Martin J. van den Bent, MD, professor, Neuro-Oncology, Erasmus MC-Daniel den Hoed Cancer Center, the Netherlands, discusses the combination of temozolomide (Temodal) and depatuxizumab mafodotin (depatux-m) in the treatment of patients with glioblastoma.

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the potential of biosimilars in oncology.

Peter O’Donnell, MD, associate professor of medicine, University of Chicago Medicine, discusses the evolution of immunotherapy in metastatic bladder cancer.

Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the FDA approval of duvelisib (Copiktra) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma.

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of pembrolizumab in melanoma.

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute discusses the significance of the CheckMate-041 trial for patients with head and neck cancer.

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, chief of the Section of Hematology/Oncology, and director of the Genitourinary Program at the University of Chicago Medicine, discusses sequencing therapies in prostate cancer.

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the use of immunotherapy in genitourinary cancer.